Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 3 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 243OTHER 184NIH 18OTHER_GOV 3NETWORK 3UNKNOWN 2INDIV 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Hodgkin Disease 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Capecitabine 2Oxaliplatin 1Irinotecan 1HMPL-013 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × UNKNOWN × Colorectal Neoplasms × Clear all
NCT05016869 2022-08-18

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

ChineseAMS

Phase 1/2 Unknown
48 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04380103 2020-05-08

A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

ChineseAMS

Phase 1/2 Unknown
106 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡